keyword
MENU ▼
Read by QxMD icon Read
search

antiemetics for chemotherapy

keyword
https://www.readbyqxmd.com/read/29055118/comparative-efficacy-and-tolerability-of-antiemetic-prophylaxis-for-adult-highly-emetogenic-chemotherapy-a-network-meta-analysis-of-143-randomized-controlled-trials
#1
Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
Chemotherapy-induced nausea and vomiting (CINV) is one of the commonest side-effects among cancer patients. However, there is lacking of hierarchical evidences comparing different antiemetics against highly emetogenic chemotherapy. Therefore, we conducted a network meta-analysis to investigate their comparative efficacy and tolerability. Randomized controlled trials that compared different antiemetic categories for adult highly emetogenic chemotherapy were included after searching PubMed, Web of Science, Embase and Cochrane Central...
October 21, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29039073/a-double-blind-randomized-phase-ii-dose-finding-study-of-olanzapine-10%C3%A2-mg-or-5%C3%A2-mg-for-the-prophylaxis-of-emesis-induced-by-highly-emetogenic-cisplatin-based-chemotherapy
#2
Takako Yanai, Satoru Iwasa, Hironobu Hashimoto, Fumiyoshi Ohyanagi, Tomomi Takiguchi, Koji Takeda, Masahiko Nakao, Hiroshi Sakai, Toshiaki Nakayama, Koichi Minato, Takahiro Arai, Kenichi Suzuki, Yasuhiro Shimada, Kengo Nagashima, Hiroyuki Terakado, Noboru Yamamoto
PURPOSE: The aim of this phase II study was to evaluate the efficacy and safety of two doses (10 and 5 mg) of olanzapine in combination with standard antiemetic treatment (aprepitant, palonosetron, and dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC). METHODS: A multi-institutional, double-blind, randomized phase II, dose-finding study of olanzapine was performed in patients with a malignant solid tumor who were receiving HEC with cisplatin (≥ 50 mg/m(2))...
October 16, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29031010/evaluation-of-aprepitant-for-acute-chemotherapy-induced-nausea-and-vomiting-in-children-and-adolescents-with-acute-lymphoblastic-leukemia-receiving-high-dose-methotrexate
#3
Femi Felix-Ukwu, Kate Reichert, M Brooke Bernhardt, Eric S Schafer, Amanda Berger
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) negatively impacts patients' quality of life. The emetogenicity of high-dose methotrexate in children and adolescents with cancer is incompletely characterized. At our institution, a number of patients with acute lymphoblastic leukemia (ALL) have received aprepitant with courses of high-dose methotrexate after poor CINV control with prior courses. PROCEDURE: We conducted a retrospective cohort analysis on patients with ALL who received methotrexate 5 g/m(2) /dose with and without concomitant aprepitant at Texas...
October 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28952201/a-phase-ii-randomised-study-to-evaluate-the-efficacy-of-aprepitant-plus-palonosetron-for-preventing-delayed-phase-cinv-associated-with-tc-therapy-in-gynaecological-cancer
#4
Yayoi Sugimori, Tsuyoshi Ota, Takafumi Ujihira, Tomonori Ishiguro, Daiki Ogishima
AIM: Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently encountered side effects of cancer treatment. Severe CINV can lead patients to refuse chemotherapy, which ultimately affects cancer outcomes. The development of fairly new antiemetic agents, 5-hydroxytryptamine-3 receptor antagonists, palonosetron and neurokinin-1 receptor antagonists and aprepitant has reduced the risk and incidence of CINV. In this study, we assessed the efficacy of aprepitant plus palonosetron against palonosetron for CINV in patients receiving moderately emetic cancer chemotherapy (paclitaxel and carboplatin combination [TC] therapy)...
September 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28948895/estimation-of-body-surface-area-in-the-musk-shrew-suncus-murinus-a-small-animal-for-testing-chemotherapy-induced-emesis
#5
Julie L Eiseman, Michael Sciullo, Hong Wang, Jan H Beumer, Charles C Horn
Several cancer chemotherapies cause nausea and vomiting, which can be dose-limiting. Musk shrews are used as preclinical models for chemotherapy-induced emesis and for antiemetic effectiveness. Unlike rats and mice, shrews possess a vomiting reflex and demonstrate an emetic profile similar to humans, including acute and delayed phases. As with most animals, dosing of shrews is based on body weight, while translation of such doses to clinically equivalent exposure requires doses based on body surface area. In the current study body surface area in musk shrews was directly assessed to determine the Meeh constant (Km) conversion factor (female = 9...
October 2017: Laboratory Animals
https://www.readbyqxmd.com/read/28941006/palonosetron-is-nonsuperior-to-ondansetron-in-acute-phase-but-provides-superior-antiemetic-control-in-delayed-phase-for-pediatric-patients-administered-highly-emetogenic-chemotherapy
#6
Juan Tan, Shan Wang, Xiaohua Liang, Chang-Chun Li, Jun Zhang, Zhenzhen Zhao, Xiang-Ru Kong, Xiaobin Deng, Liang Peng, Chao Yang
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) in children remains to be a major side effect despite antiemetic treatment. Palonosetron is a new generation 5-HT3 receptor antagonists effective against acute and delayed nausea and vomiting. This study aimed to compare the therapeutic values of palonosetron and ondansetron in preventing pediatric CINV. METHODS: A prospective, randomized, double-blind, parallel controlled study was conducted in 0-18 years old cancer patients administered highly emetogenic chemotherapy, with different dosage of palonosetron or ondansetron, both followed by dexamethasone...
September 22, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28929404/rolapitant-a-review-in-chemotherapy-induced-nausea-and-vomiting
#7
Young-A Heo, Emma D Deeks
Oral rolapitant (Varubi™; Varuby(®)), a long-acting neurokinin-1 (NK1) receptor antagonist (RA), is indicated in the USA and EU as part of an antiemetic regimen to prevent delayed chemotherapy-induced nausea and vomiting (CINV) in adults receiving highly or moderately emetogenic chemotherapy (HEC or MEC). In randomized, phase III trials, a single oral dose of rolapitant 180 mg was effective in preventing delayed CINV compared with placebo, when each was used in combination with a 5-HT3 RA plus dexamethasone, in adults receiving their first course of HEC or MEC...
September 20, 2017: Drugs
https://www.readbyqxmd.com/read/28919769/evaluating-the-antiemetic-administration-consistency-to-prevent-chemotherapy-induced-nausea-and-vomiting-with-the-standard-guidelines-a-prospective-observational-study
#8
Afsaneh Vazin, Davood Eslami, Ebrahim Sahebi
Nausea and vomiting (NV) are the most prevalent adverse effects of chemotherapy (CT). This study was conducted to evaluate adherence of the health care team to standard guidelines for antiemetics usage to prevent acute chemotherapy-induced nausea and vomiting (CINV) in a large CT center. A prospective study was performed during an 11-month period on patients receiving CT. A form was designed to collect patients' demographic information and their chemotherapeutic and antiemetic regimen data. The Likert scale was used to measure the effectiveness of the antiemetics in patients...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28917369/emesis-in-patients-receiving-acupuncture-sham-acupuncture-or-standard-care-during-chemo-radiation-a-randomized-controlled-study
#9
Ylva Widgren, Anna Enblom
OBJECTIVE: To study nausea, vomiting and need for rescue antiemetics in patients receiving antiemetic acupuncture, sham acupuncture or standard care during concomitant chemotherapy during pelvic radiotherapy. METHODS: In total, 68 patients participated (75% women, mean age 56 years, 53% had gynecological, 43% colorectal, and 4% other cancer types). Fifty-seven of them were blinded randomized to verum (n=28) or sham (n=29) acupuncture, median 10 sessions. During the study period of four weeks, the patients daily registered their nausea, vomiting and consumption of antiemetics...
October 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/28906558/effects-of-rolapitant-administered-intravenously-or-orally-on-the-pharmacokinetics-of-digoxin-p-glycoprotein-substrate-and-sulfasalazine-breast-cancer-resistance-protein-substrate-in-healthy-volunteers
#10
Xiaodong Wang, Zhi-Yi Zhang, Sujata Arora, Lorraine Hughes, Jing Wang, Daniel Powers, Jennifer Christensen, Sharon Lu, Vikram Kansra
Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. Four open-label phase 1 studies evaluated the safety and drug-drug interactions of a single dose of rolapitant given intravenously (166.5 mg) or orally (180 mg) with oral digoxin (0.5 mg) or sulfasalazine (500 mg), probe substrates for the P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), respectively...
September 14, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28871358/chemotherapy-induced-nausea-and-vomiting-cinv-and-adherence-to-antiemetic-guidelines-results-of-a-survey-of-oncology-nurses
#11
Rebecca Clark-Snow, Mary Lou Affronti, Cynthia N Rittenberg
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients with use of guideline-recommended antiemetic regimens. However, studies have suggested that adherence to antiemetic guidelines is suboptimal. Oncology nurses, as part of a multidisciplinary team, can help promote appropriate antiemetic prophylaxis. Therefore, nurses were surveyed to assess antiemetic guideline awareness and practice patterns of antiemetic use, determine adherence to guideline recommendations, and query barriers to adherence...
September 4, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28867732/comparison-between-antiemetic-effects-of-palonosetron-and-granisetron-on-chemotherapy-induced-nausea-and-vomiting-in-japanese-patients-treated-with-r-chop
#12
Mayako Uchida, Yasuo Mori, Tsutomu Nakamura, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Kaori Kadoyama, Toshihiro Miyamoto, Koichi Akashi
In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28860797/surveying-the-effect-of-a-self-care-education-program-on-severity-of-nausea-and-emesis-in-colorectal-cancer-patients-under-chemotherapy
#13
Saba Karimi, Behnam Reza Makhsosi, Seyed Jalil Seyedi-Andi, Maryam Behzadi, Yasaman Moghofeh, Kourosh Mohammadinasrabadi, Alireza Abdi, Pegah Ahmadi
BACKGROUND AND OBJECTIVE: Colorectal cancer is one of the main causes of mortality in both developed and developing countries, including Iran. One of the treatments available for colorectal cancer is chemotherapy, of which nausea and emesis are the side effects. Owing to problems in controlling the side effects, a combination of medicine and non-medicine interventions is usually used. Self-care is one of the non-medicine interventions in this regard. The present study was aimed at surveying the effect of a self-care education program on severity of nausea and emesis in colorectal cancer patients under chemotherapy...
2017: Journal of Multidisciplinary Healthcare
https://www.readbyqxmd.com/read/28855590/intranasally-administered-in-situ-gelling-nanocomposite-system-of-dimenhydrinate-preparation-characterization-and-pharmacodynamic-applicability-in-chemotherapy-induced-emesis-model
#14
Sara S Barakat, Maha Nasr, Rania F Ahmed, Sabry S Badawy, Samar Mansour
The aim of the current manuscript was to test the applicability of a nanocomposite system of penetration enhancer vesicles (PEVs) within polymeric in situ forming gel network composed of poloxamer and hyaluronic acid for the intranasal delivery of the antiemetic dimenhydrinate (DMH). PEVs were prepared using phospholipids and labrasol/transcutol/PEG 400 as penetration enhancers, and characterized for entrapment efficiency (EE%), particle size, zeta potential and morphology. The nanocomposite in situ forming gel system was characterized for its sol-gel temperature, viscosity and mucoadhesiveness, and was pharmacodynamically tested on a cisplatin induced emesis model in rats in terms of food, water, kaolin intake and stomach weight content...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28831443/survey-of-implementation-of-antiemetic-prescription-standards-in-indian-oncology-practices-and-its-adherence-to-the-american-society-of-clinical-oncology-antiemetic-clinical-guideline
#15
Vijay Patil, Vanita Noronha, Amit Joshi, Purvish Parikh, Atanu Bhattacharjee, Santam Chakraborty, Sunny Jandyal, Vamshi Muddu, Anant Ramaswamy, K Govinda Babu, Nilesh Lokeshwar, Sachin Hingmire, Nikhil Ghadyalpatil, Shripad Banavali, Kumar Prabhash
PURPOSE: Adherence to international antiemetic prophylaxis guidelines like those of ASCO can result in better control of chemotherapy-induced nausea and vomiting; however, the extent of implementation of such guidelines in India is unknown. Therefore, this survey was planned. METHODS: This study was an anonymized cross-sectional survey approved by the ethics committee. Survey items were generated from the clinical questions given in the ASCO guidelines. The survey was disseminated through personal contacts at an oncology conference and via e-mail to various community oncology centers across India...
August 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28801850/amisulpride-in-the-prevention-of-nausea-and-vomiting-induced-by-cisplatin-based-chemotherapy-a-dose-escalation-study
#16
Jørn Herrstedt, Yvonne Summers, Gedske Daugaard, Thomas B Christensen, Karin Holmskov, Paul D Taylor, Gabriel M Fox, Alexander Molassiotis
PURPOSE: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy. METHODS: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron...
August 11, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#17
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
August 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28765126/cost-utility-and-budget-impact-analyses-of-the-use-of-nepa-for-chemotherapy-induced-nausea-and-vomiting-prophylaxis-in-italy
#18
Umberto Restelli, Gabriella Saibene, Patrizia Nardulli, Roberta Di Turi, Erminio Bonizzoni, Francesca Scolari, Tania Perrone, Davide Croce, Luigi Celio
OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC)...
August 1, 2017: BMJ Open
https://www.readbyqxmd.com/read/28764837/supportive-treatments-for-patients-with-cancer
#19
Karin Jordan, Petra Feyer, Ulrike Höller, Hartmut Link, Bernhard Wörmann, Franziska Jahn
BACKGROUND: For the treatment of patients with cancer to be successful and well-tolerated, the complications and side effects of the disease and its treatment must be treated and limited as far as possible. Summarized recommendations based on the constantly increasing evidence in the area of supportive care must be defined, standardized, and communicated. METHODS: We systematically reviewed the literature on the topics of anemia, neutropenia, nausea/vomiting, diarrhea, oral mucositis, skin toxicity, and peripheral neurotoxicity induced by cancer treatment, as well as osseous complications, extravasation, and side effects of radiotherapy...
July 10, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28759346/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update
#20
REVIEW
Paul J Hesketh, Mark G Kris, Ethan Basch, Kari Bohlke, Sally Y Barbour, Rebecca Anne Clark-Snow, Michael A Danso, Kristopher Dennis, L Lee Dupuis, Stacie B Dusetzina, Cathy Eng, Petra C Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, Mark R Somerfield, Gary H Lyman
Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included in this systematic review. A phase III randomized controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelihood of nausea among adult patients who are treated with high emetic risk antineoplastic agents. Randomized controlled trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are treated with chemotherapy...
October 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"